Starting treatment: latest news

Starting treatment resources

Starting treatment features

Starting treatment in your own words

Starting treatment news from aidsmap

  • Atripla or efavirenz plus Truvada failed one in 16 people in first year

    Estimates of how often people on antiretroviral therapy (ART) do not remain virally undetectable are important both in order to gauge the potency of ART, and to answer the question of how often people with HIV maintain undetectable viral ...

    21 January 2019 | Gus Cairns
  • HIV treatment outcomes continue to get better, says large analysis

    The efficacy of first-line antiretroviral therapy (ART) continues to improve, according to an analysis of outcomes in 78,000 people in 181 studies, published in AIDS by Professor Andrew Carr of St Vincent's Hospital in Sydney and colleagues. Over ...

    27 December 2018 | Michael Carter
  • All people with HIV-2 should receive HIV treatment – without it, most will progress to AIDS and death

    Most people with HIV-2 infection will progress to AIDS and death unless they receive antiretroviral therapy (ART), according to the results of a study conducted in Guinea-Bissau and published in The Lancet HIV. HIV-2 infection has been considered more benign than ...

    27 November 2018 | Michael Carter
  • Early HIV treatment reduces the risk of liver fibrosis

    Early antiretroviral therapy (ART) reduces the risk of liver fibrosis progression in people living with HIV, including in people who do not have co-infection with viral hepatitis, according to the results of the START study published in Hepatology.People with a ...

    08 November 2018 | Michael Carter
  • Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

    Dolutegravir-based treatment was no more effective than treatment based on a 400mg dose of efavirenz, a randomised trial conducted in Cameroon has found. However, almost half of people with very high viral loads taking either regimen had a ...

    01 November 2018 | Keith Alcorn
  • Bictegravir matches dolutegravir in first-line treatment

    A triple combination containing the new integrase inhibitor bictegravir proved just as effective as a dolutegravir-based combination in suppressing viral load over 96 weeks, but people taking bictegravir experienced significantly fewer adverse events related to treatment, Professor Hans-Jürgen Stellbrink of the ...

    31 October 2018 | Keith Alcorn
  • Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects

    Antiretroviral treatment with a boosted protease inhibitor and one other drug is just as effective as three-drug antiretroviral therapy containing a boosted protease inhibitor but results in fewer treatment discontinuations due to side-effects, a meta-analysis presented at the International ...

    30 October 2018 | Keith Alcorn
  • Studies confirm long-term effectiveness of new single-tablet regimens

    The newest once-daily, all-in-one HIV combination pills can maintain undetectable viral load for two years and counting, according to a set of studies presented at IDWeek 2018 this month in San Francisco. Two phase 3 clinical trials showed that ...

    18 October 2018 | Liz Highleyman
  • Doravirine combination works well as a switch option

    A combination pill containing doravirine (Delstrigo) maintains undetectable viral load in people with well-controlled HIV who switched therapy, and continues to provide sustained viral suppression at 96 weeks for newly treated people, according to research presented at IDWeek 2018 last ...

    08 October 2018 | Liz Highleyman
  • Two new doravirine pills approved in US

    The US Food and Drug Administration (FDA) has approved two new products containing the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine. These products are also under review by the European Medicines Agency.Produced by Merck/MSD, Pifeltro is a stand-alone doravirine tablet that ...

    12 September 2018 | Liz Highleyman
More news

Starting treatment news selected from other sources

More news
Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.